NCCMP Hot Topics: New Drugs for Weight Loss Telehealth Update Peri-COVID

September 13, 2023


Presenters: Sadhna Paralkar, MD / Eileen Pincay RPh, Moderator: Breanna Radtke

© 2023 by The Segal Group, Inc.

# Weight Loss



### The Obesity Rate of the U.S. Population Has Almost Doubled in Recent Decades



Source: Centers for Disease Control and Prevention. Health, United States, 2020-2021

**Segal** 3

### What are GLP-1 Medications?

GLP-1 is a hormone found naturally in our bodies that targets the area of the brain that regulates appetite and is insufficient in people who have type 2 diabetes.

**Diabetes** 

Medications mimic GLP-1 hormone and help lower blood sugar Weight Loss Medications mimic GLP-1 hormone and help regulate appetite




### History of GLP-1 Medications

Until recently GLP-1's considered a second-line agent to treat diabetes 2021, ADA recommends prescribing GLP-1s to reduce health complications regardless of A1C or metformin use 2023 ADA guidelines emphasizes both supporting higher weight loss and focusing on obesity as chronic disease

#### Led to increased utilization of GLP-1s for diabetes AND weight loss



### Plan Spending on Anti-Diabetic Medications with Weight Loss is Rising Steadily




Source: Segal SHAPE, Segal's data warehouse, 2018 to 2022

```
🔆 Segal 🛛 🤅
```

### Off-Label Weight-Loss Drug Usage

2021 – 2022 GLP-1 Utilizer History<sup>1</sup>



7

1. Historical lookback began with date of first GLP-1 medication fill, members may have utilization of more than 1 medication in this class subsequently


### **Utilization Concerns**

- Off label use of diabetes GLP-1 therapies (i.e. Ozempic) for weight loss
- Social media has been a big contributor to using Ozempic for weight loss which, in turn, has caused drug shortages.
- PBMs are offering utilization management programs to curb off-label spend for the GLP-1 medications.
- GLP-1s are likely to become the number one drug cost therapy for many plan sponsors by 2024.



# Obesity GLP-1 Medication Costs Compared to Diabetes GLP-1 Medications


#### 30-day Rx Cost [2023 YTD]



Note that prices listed are mean charges after PBM discounts but before rebate offsets



### Dramatic Increase in Anti-Obesity Medication Spending due to GLP-1s



### Various PBM Cost Management Strategies

Smart logic to screen out patients who have

Use utilization management to ensure the diabetic GLP-1 drugs are only used for patients with diabetes

2 3


(if available) and prescription claims history to bypass PA requirements. Doctor office to confirm diagnosis and "attest" to it in a PA

diabetes. Smart logic utilizes both ICD diagnosis codes

Doctor office to confirm diagnosis and "attest" to it in a PA case

Move from step therapy to prior authorization approach

Be sure to consider any potential rebate impact




X Segal 11


### Are Plans Covering Weight Loss Drugs and What Is Impact?

- Employers Health, a large group-purchasing organization for pharmacy benefits for 2021 reported 60% of clients exclude obesity drugs and 25% cover them with a PA.
- Medicare does not cover obesity drugs, but does cover bariatric surgery and intensive behavioral therapy
- In 2018, the average cost for Segal clients who cover weight-loss medications was \$0.50 PMPM and by 2022, it was \$2.21 PMPM.

https://info.mmitnetwork.com/hubfs/AHD%20Friday%20Infographics/coverage-of-weight-lossmedications.png?utm\_campaign=AIS%20Health%20Daily&utm\_medium=email&\_hsmi=242188090&\_hsenc=p2ANqtz-9Pg2vwJx5BQiFjoGmxuIMvtw1Dy-WX\_AF11dsJXR7fkZ40UHPED7MsLUJPm-OpsmEmdGy52x\_QWIURo8hTY8OLTja56g&utm\_content=242188090&utm\_source=hs\_email



### Plan Spending on Weight-Loss Medication Continues to Shift Towards GLP-1s



### Weight-loss Options Vary in Cost and Effectiveness

	Traditional Diet & Exercise Programs	Provider-Led Clinical Weight Loss	GLP-1 Drugs	Bariatric Surgery
Avg weight loss at ~ 1 year (% reduction in body weight)	0–5%	13%	15%+	20%+
Est. List Price (for one year of treatment)	\$500	\$1,800	\$12,000+	\$20,000+
	Chin, S., Keum, C., Woo, J. et al. Successful weight reduction and maintenance by using a smartphone application in those with overweight and obesity. Sci Rep. 2016; 6, 34563, Noom list price	NcKenzie AL, et al. Nutrients. 2021; 13(3):749 Outcomes among one year completers, Virtaust price	Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Novo Nordisk; list price. https://www.novocare.com/wegovy/let-us-help/ explaining-list-price.html - \$1309.42 per	NTMC, "How much does bariatric surgery cost," Accessed 1/25/2023, Maciejewski ML, Arterburn DE, Van Scoyoc L, Smith VA, Yancy WS Jr, Weidenbacher HJ, Livingston EH, Olsen MK. Bariatric Surgery and Long-term Durability of Weight Loss. JAMA Surg. 2016 Nov 1;151

package. Accessed 10/18/22



### Steps in Managing GLP-1 Spend



Acquire Rx

- Program eligibility
- Health coaching PA •
- Bridge to Physician .
- Troubleshoot access ٠







- Trust as foundation
- Match and move .
- Guiding adherence .
- Monitoring efficacy •



**Titrate Rx** 

- Objective weight loss
- Sustained behavior change ٠
- Other condition improvements .
- Support Physicians/participants .



#### Sustained Weight Loss

- Ongoing Coach relationship ٠
- Continued data monitoring .
- Generalizable skills/strategies .

🕂 Segal

15

Maximization of resources .

## The Bigger Picture for Managing Obesity

- Assess and reevaluate current obesity treatments under the medical benefit.
- Update patient education and access to lifestyle weight-loss programs
- Offer access to low-cost fitness programs
- Implement UM guidelines for all AOMs
- Require patients to be in a behavioral health management program



## The Bigger Picture for Managing Obesity

- Negotiate lowest-net-cost PBM formulary changes
- Provide educational support for appropriate and safe exercising.
- Offer access to virtual coaching
- Implement accountability check-ins with patients
- Consider implementing stricter coverage to target smaller group of plan participants
- Seek outcomes based performance guarantees with PBMs when adding coverage of these high cost anti-obesity meds tied to achieving minimum average weight loss amounts (e.g. at least 10% weight loss after 6 months use).

### Need for Health Coaching

- Needs whole person care, not just medication access
- Health coaching is of paramount importance in order to:
  - Build ongoing, trusted relationship with the recipient of the medication
  - Monitor the medication side effects and interactions
  - Address the medication goal areas and adherence
  - Discuss dosages, interactions, side effects and concerns related to the medication
  - Can advocate, speak directly with physician or pharmacy
  - Monitor and help manage medication tolerance and contraindications
  - Could be in person or virtual



### Goal: Sustainable Weight Loss


- Continued behavior change coaching for 1-2 years post treatment
- Build and activate ongoing support network for each participant
- Learned and lasting behavior change
  - Weight management
  - Nutrition advice
  - Exercise advice
  - Medication adherence
  - Stress, sleep, other disease state management
- Importance of physical health and wellbeing is established
- Relapse prevention



# Telehealth Update – peri-COVID



### Telehealth Impact



## Conditions with the greatest increase in visits

Rank	Category	Change
	Trauma- and stressor-related	
1	disorders	42,018%
2	Feeding and eating disorders	34,703%
	Obsessive-compulsive and related	
3	disorders	34,177%
4	Alcohol-related disorders	27,878%
5	Medical examination/evaluation	24,571%
6	Anxiety and fear-related disorders	24,527%
7	Multiple sclerosis	21,920%
8	Cannabis-related disorders	18,440%
9	Depressive disorders	17,912%
10	Neurodevelopmental disorders	14,469% <sub>1</sub>


### Variation in telehealth adoption by US State

	State	<b>Payment Parity</b>	% Telehealth Adoption
Top 10 States	Hawaii	Yes	22%
	California	Yes	20%
	District of Columbia	No	19%
	Massachusetts	Yes	17%
	Oregon	No	14%
	Maryland	Yes	13%
	Delaware	Yes	12%
	Rhode Island	Yes	12%
	Vermont	Yes	12%
	Connecticut	Yes	12%
	Mississippi	No	7%
S	Missouri	No	6%
te	Alaska	No	6%
Bottom 10 States	Alabama	No	6%
	Tennessee	No	6%
	Montana	No	6%
	South Dakota	No	5%
	North Dakota	No	5%
	Nebraska	Yes	5%
	lowa	Yes	4%




### Trends in outpatients via telemedicine

Telehealth Trend by Medical Specialty



23

### Trends in outpatients via telemedicine



Source: Telehealth Adoption after Pandemic

**Segal** 24



- Should plan sponsors consider potential long-term health savings from lower obesity rates vs. higher near-term Rx costs today?
- Are these drugs more effective from both outcome and cost perspectives, than bariatric surgery?
- Can the plan limit coverage for these drugs to a specific BMI, such as 40+?
- If a plan covers weight loss drugs, how long before they are likely to see an ROI from all of illnesses associated with obesity.
- Should we encourage or discourage use of obesity fighting drugs?
- What's Telehealth going to look like in 2030?

# Impact of Insulin Price Decreases



### Insulin – New Drug Pricing Dynamics

- In March 2023, the three leading insulin manufacturers (Lilly, Novo Nordisk, and Sanofi) announced major price decreases of up to 75% for some of their insulin products.
- Starting January 1, 2024, the American Rescue Plan Act will remove the rebate cap which affects what manufacturers pay.
- This in turn will have an impact on the rebates paid by manufacturers to PBMs and rebate aggregators.
- PBMs are approaching this pricing update in various ways.

Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at \$35 Per Month

News Release

Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-ofpocket Lantus costs at \$35 for all patients with commercial insurance

March 16, 2023

US PRESS RELEASE

Novo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024



### Thank You

**Eileen Pincay, RPh** Vice President and National Pharmacy Practice Leader epincay@segalco.com

Sadhna Paralkar, MD Senior Vice President and National Medical Director SParalkar@segalco.com





